Quick Answer
Silo Pharma, Inc. reported Research And Development Expense of $2.16 million for the year ending 2025.
- Silo Pharma, Inc. showed a decrease of -8.8% in Research And Development Expense from 2024 to 2025.
- This data is from Silo Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $48.6 thousand | Q2 2021: $98.8 thousand | Q3 2021: $70.5 thousand | Q1 2022: $170.3 thousand | Q2 2022: $105.7 thousand | Q3 2022: $375.8 thousand | Q1 2023: $202.9 thousand | Q2 2023: $130.7 thousand | Q3 2023: $174.5 thousand | Q1 2024: $318.2 thousand | Q2 2024: $392.8 thousand | Q3 2024: $517.5 thousand | Q1 2025: $594.0 thousand | Q2 2025: $717.2 thousand | Q3 2025: $543.6 thousand.
- Over the full 6 years of available data (2020 to 2025), Silo Pharma, Inc.'s Research And Development Expense has grown by 8,131.7%.
- Historical annual values: Fiscal year 2025: $2.16 million | Fiscal year 2024: $2.37 million | Fiscal year 2023: $845.1 thousand | Fiscal year 2022: $1.29 million | Fiscal year 2021: $693.9 thousand | Fiscal year 2020: $26.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: